American Journal of Gastroenterology Publishes Key Study Further Validating Esopredict® as a Prognostic Test for Barrett’s Esophagus (PR Newswire)

Previse has announced new clinical validation for Esopredict®, a groundbreaking test that uses DNA methylation to assess the risk of esophageal cancer in patients with Barrett’s esophagus. Published in the American Journal of Gastroenterology, the study confirms Esopredict’s reliability across different biopsy locations and time points, reinforcing its role in early risk stratification. This advancement enables earlier intervention for high-risk patients while reducing unnecessary procedures for those at lower risk. Learn more about how Esopredict is shaping the future of GI cancer prevention.